# Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Source: https://onco.cc/trials/nct05669482/  
OnCo record `nct05669482` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in metastatic cancer, run by Verastem, Inc., active and no longer recruiting.

## Summary

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05669482 by Verastem, Inc., with 40 participants planned, started 2023-03-22 and due to reach its primary completion in 2026-08-31. Interventions recorded: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel. Conditions listed: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05669482
- Phase: 1/2
- Setting: A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
- Sponsor: Verastem, Inc.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05669482: https://clinicaltrials.gov/study/NCT05669482

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)

---
JSON: https://onco.cc/api/v1/entities/nct05669482.json